The Latest
-
Kevin Dietsch via Getty Images
Tariffs are back. What does it mean now for pharma?
While the Trump administration has again levied large new tariffs, drugmakers willing to make deals could gain some relief.
-
Getty Images
AI’s next trick? Revealing new disease targets for drug R&D
A wave of AI-driven platforms bucks the traditional approach of hunting for new molecules and instead focuses on pinpointing the underlying cause of disease.
-
Retrieved from NASA's Moderate Resolution Imaging Spectroradiometer.
How Trump’s war in Iran is scrambling pharma’s shipping options
A blockade at one of the world’s largest shipping lanes could shape the way pharma companies think about manufacturing and distribution.
-
Getty Images
Will Pfizer’s Lyme disease gamble pay off or set the space back?
As the disease spreads into new regions, the urgency for prevention is growing.
-
Getty Images
Big Pharma goes nuts over food allergies — again
Novartis’ acquisition of Excellergy for up to $2 billion portends a potential new wave of medicines for food allergies.
-
Getty Images
mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts
Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.
-
Getty Images
The FDA’s shame game
The agency is becoming more open about its criticisms of pharma companies and leaders, raising new privacy concerns in the industry.
-
Getty Images
Can Ocugen succeed where other gene therapy makers have struggled?
The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization challenges that have dogged the space.
-
Courtesy of Novo Nordisk
Novo’s FDA voucher victory; biotech’s rigid glass ceiling
While Novo Nordisk collected a win through the FDA’s new voucher program, the initiative remains unpredictable and controversial.
-
Getty Images
Q&AHow former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.
-
Getty Images
Mixed signals cloud the orphan drug market
The field is making gains despite regulatory inconsistency, but rising competition from obesity candidates and evolving global pressures could erode orphan drugs’ market share.
-
Getty Images
Women in biotech hit a leadership plateau as board barriers persist
A new initiative from BioIndustry Association and AstraZeneca aims to boost representation on heavily dominated male boards.
-
Getty Images
How AI is reshaping clinical trials
Human oversight remains crucial as the technology is leveraged in safety monitoring, boosting clinical trial diversity and more.
-
Permission granted by Gilead Sciences
Deep DiveGilead could potentially end HIV. But will it be able to?
After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.
-
Scott Olson via Getty Images
Lilly’s manufacturing bet; hints of a biotech revival
Lilly is investing billions more into Chinese manufacturing — and other topics on our radar this week.
-
Getty Images
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.
-
Getty Images
As Chinese biotechs recognize their value, the bargain era may be over
Rising average upfront payments signal that buyers see value in Chinese assets.
-
Getty Images
Q&AVC sees early signs of a biotech market spring as long winter fades
The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.
-
Getty Images
Federal court blocks RFK Jr.’s moves to upend US vaccine policy
HHS ignored established protocols in altering the childhood immunization schedule and overhauling a CDC panel, according to the ruling.
-
Permission granted by Bayer
What’s at stake for Bayer in its Supreme Court showdown?
A key case being heard by the Supreme Court could help the large pharma put its Roundup litigation to rest.
-
Courtesy of Novo Nordisk
Novo regained weight loss footing in the pill arena — but Lilly is coming
Eli Lilly has run away with the GLP-1 market. But can Novo Nordisk maintain pole position in the oral space?
-
Alamy
Keytruda’s reign continues; pharma’s megadeal drought
Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our radar this week.
-
Getty Images
New FDA guidance could elevate pharma’s biosimilar market
Biologic copycats are making a bigger impact on drug prices as U.S. regulators open the doors wider, and new guidance could improve their standing even more.
-
Permission granted by Merck & Co.
Keytruda and Padcev could become cancer’s power couple
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
-
Getty Images
Servier’s $2.5B cancer bet underlines a quick oncology growth strategy
Relatively new to the oncology scene, Servier has built a reputation as a serial acquirer of targeted cancer outfits as it pumps up its pipeline.
